Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
27.71
-0.44 (-1.56%)
At close: Mar 23, 2026, 4:00 PM EDT
27.51
-0.20 (-0.72%)
Pre-market: Mar 24, 2026, 5:31 AM EDT
Alkermes Revenue
In the year 2025, Alkermes had annual revenue of $1.48B, down -5.25%. Alkermes had revenue of $384.55M in the quarter ending December 31, 2025, a decrease of -10.57%.
Revenue (ttm)
$1.48B
Revenue Growth
-5.25%
P/S Ratio
3.13
Revenue / Employee
$719,951
Employees
2,050
Market Cap
4.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.48B | -81.73M | -5.25% |
| Dec 31, 2024 | 1.56B | -105.77M | -6.36% |
| Dec 31, 2023 | 1.66B | 551.61M | 49.61% |
| Dec 31, 2022 | 1.11B | -61.96M | -5.28% |
| Dec 31, 2021 | 1.17B | 135.00M | 13.00% |
| Dec 31, 2020 | 1.04B | -132.19M | -11.29% |
| Dec 31, 2019 | 1.17B | 76.67M | 7.01% |
| Dec 31, 2018 | 1.09B | 190.90M | 21.13% |
| Dec 31, 2017 | 903.37M | 157.68M | 21.15% |
| Dec 31, 2016 | 745.69M | 117.36M | 18.68% |
| Dec 31, 2015 | 628.34M | 9.55M | 1.54% |
| Dec 31, 2014 | 618.79M | 43.24M | 7.51% |
| Mar 31, 2013 | 575.55M | 185.57M | 47.59% |
| Mar 31, 2012 | 389.98M | 203.34M | 108.95% |
| Mar 31, 2011 | 186.64M | 8.36M | 4.69% |
| Mar 31, 2010 | 178.28M | -148.56M | -45.45% |
| Mar 31, 2009 | 326.84M | 86.12M | 35.78% |
| Mar 31, 2008 | 240.72M | 752.00K | 0.31% |
| Mar 31, 2007 | 239.97M | 73.36M | 44.04% |
| Mar 31, 2006 | 166.60M | 90.48M | 118.85% |
| Mar 31, 2005 | 76.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dr. Reddy's Laboratories | 3.85B |
| Amneal Pharmaceuticals | 3.02B |
| Hims & Hers Health | 2.35B |
| Lantheus Holdings | 1.54B |
| Phibro Animal Health | 1.46B |
| Prestige Consumer Healthcare | 1.10B |
| BioCryst Pharmaceuticals | 874.84M |
| Supernus Pharmaceuticals | 718.95M |
ALKS News
- 11 days ago - Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program - Business Wire
- 13 days ago - Alkermes to Present at the Stifel 2026 Virtual CNS Forum - Business Wire
- 26 days ago - Alkermes plc (ALKS) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 - Business Wire
- 26 days ago - Alkermes plc Announces CEO Succession Plan - Business Wire
- 27 days ago - Alkermes to Present at the TD Cowen 46th Annual Health Care Conference - Business Wire
- 5 weeks ago - Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market - Business Wire
- 5 weeks ago - Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026 - Business Wire